Introduction

Approximately 171 million people worldwide have diabetes, and this number is increasing. Diabetes mellitus is a chronic illness, characterised by hyperglycaemia resulting from impairments in insulin secretion, defects in insulin action, or both. The classification of diabetes has moved away from a system where the disease was distinguished based on the requirement for insulin therapy, to one based on the pathogenesis of the disease, wherever possible (see Table I).

The correct classification is important because of the different therapeutic options available to treat the different forms of diabetes. Worldwide, the incidence of type 1 diabetes is increasing, with more children being obese on presentation as a result of the escalating prevalence of obesity in the youth. In addition, there is an epidemic of type 2 diabetes in adolescents. Clinical distinction is difficult, not only because of the overlap in clinical presentation between obese type 2 diabetic patients and obese children with type 1 diabetes, but also as a result of other forms of diabetes present in the age group < 45 years [maturity onset diabetes in the young (MODY) and latent autoimmune diabetes in adults (LADA)]. An educated decision regarding the type of diabetes can be made based on family history and laboratory tests, including tests for autoimmune markers. However, these types of tests are expensive, and are not readily available in resource-poor African countries.

Anumber of autoantibodies, genes and environmental factors have been shown to be associated with type 1 diabetes. Worldwide, these risk factors have been extensively studied to differentiate type 1 diabetes from other forms of diabetes. The question arises as to whether or not the genetic and autoimmune associations seen in the rest of the world hold true in African type 1 diabetics. In South Africa, and Africa in general, there is sparse information regarding the epidemiology of this disease, and it is poorly characterised in the black population. This review will provide an overview of the epidemiological, immunological and genetic data that have been generated on type 1 diabetes in Africa, especially in the black population.

Table I: Aetiological classification of diabetes mellitus

| Diabetes mellitus                                                                 |
|-----------------------------------------------------------------------------------|
| Type 1 diabetes (β cell destruction, usually leading to absolute insulin deficiency) |
| • Autoimmune (type 1A)                                                            |
| • Idiopathic (type 1B)                                                            |
| Type 2 diabetes (results from a progressive insulin secretory defect on the background of insulin resistance) |
| Other specific types of diabetes, e.g. genetic defects of β cell function or insulin action, diseases of the exocrine pancreas, or drug- or chemical-induced diabetics |
| Gestational diabetes (diagnosed during pregnancy)                                 |
Type 1 diabetes mellitus

Type 1 diabetes is caused by the autoimmune destruction of the insulin-producing β cells of the pancreas. The destruction process is marked by infiltration of the pancreatic islets by mononuclear cells, and may take place over a period of many years. A large proportion (> 80%) of the β cells are destroyed by the time clinical symptoms appear.

In 2000, it was estimated that 171 million adults 20 years of age or older have diabetes. Type 1 diabetes accounts for 5-10% of all cases of the disease. The majority of patients (approximately 40%) are diagnosed and classified with type 1 diabetes within the first two decades of life, making it one of the most common severe chronic diseases of childhood. However, an increasing number of cases are being recognised in older individuals. In the USA, 1:300 children, and as many as 1:100 adults, develop this disease.

There is a large geographical variability in the incidence of type 1 diabetes. Scandinavia (36.5/100 000 per year in Finland) and the Mediterranean island of Sardinia (36.8/100 000 per year) have the highest incidence rates in the world, while Oriental populations have the lowest rates (0.1/100 000 per year in China). There are few articles in the literature reporting the incidence and prevalence of type 1 diabetes in Africa. Table II summarises the data obtained from African countries.

The incidence of type 1 diabetes changes with age. The incidence increases from birth to 12 years, reaching a peak at 10-14 years of age, before falling to a much lower rate. Studies conducted among African populations have shown a peak incidence of type 1 diabetes at 20-29 years of age, which is a decade later than that observed in Caucasian populations. The reasons for this later age of onset in Africans are not known.

In most instances, there is no difference in the incidence of type 1 diabetes in males and females, with the pubertal peak of incidence in females preceding that in males by one to two years. In Africa, there seem to be conflicting reports regarding the gender ratios of black patients with type 1 diabetes (see Table II). Studies carried out among Ethiopian and Nigerian type 1 diabetes patients found a two- and threefold higher incidence of type 1 diabetes in males compared to females, respectively. In contrast, a study carried out among black South African type 1 diabetics, and a second study on Sudanese patients, found a slightly higher incidence of female to male patients, although this was not statistically significant. A female predominance was shown in Libyan type 1 diabetic patients in the age range 0-14 years, but a male predominance in the age group 15-34 years. When all the patients were taken as a whole, there was a male predominance in the incidence of type 1 diabetes.

Table II: The prevalence/incidence of type 1 diabetes in Africa

| Country          | Prevalence | Incidence | Male:female ratio | Age range                  |
|------------------|------------|-----------|-------------------|----------------------------|
| Algeria          | 0.27/1 000 | 8.1/100 000 | Twice as high in males as in females | < 20 years                  |
| Ethiopia         | 2.1/100 000| 7.8/100 000 | Excess risk for females vs. males | 0-14 years                  |
| Ghana            | 0.75/1 000 | 0.95/1 000  | Increased incidence of male to female. Female predominance in group aged 0-14 years, male predominance in group aged 15-34 years. | < 35 years                  |
| Libyan           | 0.25-0.46/1 000 | 3.1:1 male:female prevalence ratio | 5-17 years |
| North-West Nigeria | 3.1/1 000 | 10.1/100 000 | Slightly higher in females than males | 0-14 years. Peaks at 12 and 14 years in females and males, respectively |
| Sudan            | 0.95/1 000 | 0.95/1 000 | Slightly higher in females than males | 7-14 years                  |
| Tanzania         | 1.5/100 000 | 6.76/100 000 | No difference | 0-19 years. Incidence increased with age |
| Tunisia          | 6.95/100 000 | 6.95/100 000 | No difference | 0-19 years                  |
Autoimmunity

Autoantibodies in type 1 diabetes

Autoantibodies are currently the most frequently used markers for the prediction of type 1 diabetes. The most prevalent autoantibodies are directed at the 65 kDa isoform of glutamic acid decarboxylase (GAD65; 70-80%), the tyrosine phosphatase-like protein (IA)-2 (50-80%), and insulin (IAA; ± 50% in newly-diagnosed children).25-27 Up to 90% of newly diagnosed type 1 diabetic patients have autoantibodies to one or more of these autoantigens. The percentage positivity depends on the age and ethnicity of the patient, as well as the duration of the disease. These autoantibodies can be present in the serum of prediabetic individuals years before clinical diagnosis, and the presence of all three autoantibodies is highly predictive of future type 1 diabetes development.28

There are very limited epidemiological, immunological and genetic data available for the African type 1 diabetes population, especially in southern Africa. Over the past 30 years, there have been approximately 15 publications, the majority from northern Africa, reporting on the presence of autoantibodies in the serum of African type 1 diabetic patients. The majority of papers have only addressed the presence of islet cell antibodies (ICAs).

As seen in Table III, there is wide variation in the frequency of ICAs within Africa.29-36 The observed frequencies are lower than those reported in Caucasian type 1 diabetic populations.37 Less than a third of the publications considered the presence of two or more autoantibodies. The prevalence of GAD autoantibodies was studied in 84 Tunisian type 1 diabetic children.36 With increasing duration of type 1 diabetes, the prevalence of GAD autoantibodies decreased: 84.6% of children with newly-diagnosed diabetes (< 6 months) were positive for GAD autoantibodies, as opposed to only 29.41% in those with a longer duration of disease (> 5 years). In another study, 47 type 1 diabetes patients from Cameroon were screened for GAD and IA-2 autoantibodies.38 The mean disease duration was 3.3 years. Sixteen patients and three patients were GAD- and IA2-autoantibody-positive, respectively. Similarly, a study carried out in Tanzania revealed lower frequencies of GAD and IA-2 autoantibodies compared to Caucasian type 1 diabetic patients.37,39 Only one paper looked at the frequency of all four autoantibodies in 86 newly diagnosed type 1 diabetic children from Tunisia.31 The authors found that 78 (90.7%) children were positive for one or more autoantibody. Only three papers were identified that reported the screening of black South Africans for the presence of disease-associated autoantibodies. In the first paper, ICAs were found in over a third of black and Indian South African patients.40

Table III: The prevalence of type 1 diabetes associated autoantibodies in African populations

| Study population | Number and type of patients | ICA+  | GAD65+ | IA-2+ | IAA+ |
|------------------|-----------------------------|-------|--------|-------|------|
| Ethiopia29        | 43 newly diagnosed black    | 39%   | -      | -     | -    |
| Tunisia30         | 175 black                   | 45.1% | -      | -     | -    |
| Tunisia31         | 86 newly diagnosed black    | 57%   | 65.1%  | 43%   | 50%  |
| Sudan12          | 46 newly diagnosed black    | 63%   | -      | -     | -    |
| Sudan13          | 96 black                    | 41.7% | -      | -     | -    |
| Nigeria24        | 68 black                    | 5.9%  | -      | -     | -    |
| Tanzania15       | 35 newly presenting black   | 8.6%  | -      | -     | -    |
| Tunisia26        | 84 black                    | 21.4% | 51.2%  | -     | -    |
| Cameroon28       | 47 black                    | -     | 34%    | 6.4%  | -    |
| Tanzania29       | 94 black                    | -     | 21.3%  | 12.8% | -    |
| South Africa40   | 47 black                    | 36.2% | -      | -     | -    |
|                   | 34 Indian                   | 32.4% | -      | -     | -    |
| South Africa41   | 100 black                   | -     | 44%    | -     | -    |
| South Africa42   | 43 black                    | -     | 33%    | -     | -    |
|                   | 17 Caucasian                | -     | 67%    | -     | -    |
| America37        | 113 black                   | 58%   | 54%    | 38%   | 20%  |
|                   | 117 Caucasian               | 77%   | 73%    | 65%   | 35%  |
remaining two studies examined the presence of GAD autoantibodies, and found a lower prevalence in black type 1 diabetic patients, compared to Caucasian type 1 diabetic patients.\textsuperscript{41,42}

**Autoantibodies and latent autoimmune diabetes in adults**

GAD65 and insulin autoantibodies were also found in 5-10\% of patients classified with type 2 diabetes.\textsuperscript{43,44} Initially, these patients have residual $\beta$-cell function, sufficient to prevent the development of acute metabolic decompensation (ketosis) for many years. However, the $\beta$-cell mass declines over time, thus necessitating insulin treatment.\textsuperscript{45} This slowly progressing form of type 1 diabetes is termed LADA, or type 1.5 diabetes.\textsuperscript{44,46} The Immunology of Diabetes Society has proposed the following definition for LADA: patients must be $\geq$ 30 years of age, be positive for at least one autoantibody, and require no insulin within the first six months following diagnosis.

There is sparse information on the presence or absence of LADA in Africa. One reason for this may be the difficulty in classifying the different types of diabetes. In a study conducted in 124 type 2 diabetic patients from Nairobi, it was found that 79\% were “true” type 2, 5.7\% were LADA, 12.1\% were type 1B, and 3.2\% were type 1A diabetics.\textsuperscript{47} Similar findings were reported in a study of 103 non-insulin-requiring diabetic patients from Ghana.\textsuperscript{13} Seventeen (16.5\%) of the non-insulin-requiring patients were positive for ICA and/or GAD and/or IAA, and the prevalence of LADA in this group was 13.5\%.\textsuperscript{13} Thus, clinical judgement alone cannot be used to classify patients, and may be one of the reasons for the poor glycaemic control seen in a number of diabetic patients.

**Susceptibility to type 1 diabetes mellitus**

The rapid increase in the incidence of type 1 diabetes (3.9\% average annual increase in Europe over the period 1989-2003) cannot be accounted for by genetics alone.\textsuperscript{46} A seasonal variation in the incidence of type 1 diabetes has been observed. There is a decline during the warm summer months.\textsuperscript{49} However, this seasonal pattern only appears to occur in older children and adolescents, suggesting that factors triggering diabetes may be related to school attendance or viral infections.\textsuperscript{50}

In Africa, as in the rest of the world, there are confounding reports as to whether or not viruses are a significant factor in the aetiology of type 1 diabetes. A study of 40 insulin-treated Nigerian diabetics did not show any association of Coxsackie B1, mumps, rubella and enterovirus group antigen with type 1 diabetes. The non-diabetic control samples (who were matched for age, sex and social status) had significantly higher levels of Coxsackie A virus compared to the diabetic patients.\textsuperscript{51} Thus, in this group, previous exposure to these viruses is not a trigger of type 1 diabetes. A second study conducted on 40 newly diagnosed type 1 diabetic patients (> 1-year duration of disease; Group 1), 30 type 1 diabetic patients (< 1-year duration; Group 2) and 30 healthy non-diabetic children from Egypt showed a significant increase in the evidence of viral infection in Group 1 and Group 2 vs. the control subjects.\textsuperscript{52}

**Genetic susceptibility**

Type 1 diabetes is a heterogeneous and polygenic disorder. There are currently more than 40 gene loci that have been linked with influencing type 1 diabetes risk. The two major susceptibility regions that have been identified are IDDM1, the major histocompatibility complex region on chromosome 6p21, and IDDM2, the insulin gene region on chromosome 11p15.5.\textsuperscript{53}

The best studied is IDDM1, which contains the human leukocyte antigen (HLA) genes that code for HLA class II antigens. Fine mapping of this locus suggests that two HLA haplotypes, DR3 and DR4, are strongly associated with type 1 diabetes susceptibility.\textsuperscript{54} The vast majority (90\%) of type 1 diabetics have either DR3, DQ2 (DQ2 = DQA1*0501, DQB1*0201) or DR4, DQ8 (DQ8 = DQA1*0301, DQB1*0302) haplotypes, whereas 40-50\% of most non-diabetics have one or the other of these haplotypes. Between 30-50\% of patients with type 1 diabetes are heterozygotes with DR3, DQ2/DR4, DQ8 compared with only 2.4\% of the general population.

A number of studies have analysed the frequency of HLA antigens in African type 1 diabetic patients. One study conducted in Algerian type 1 diabetic patients found a strong association of DR3 with type 1 diabetes. DR4 was found to be equally distributed in patients and controls (21\% vs. 28.4\%). However, the DR3 and DR4 heterozygous allele was present more frequently in diabetics.\textsuperscript{55} A second study found a higher frequency of the haplotypes (DR3DQ2 or DR4DQ8) in diabetics (85\%) vs. controls (34\%), and 42\% of the patients had the heterozygous haplotype DR3DQ2/ DR4DQ8.\textsuperscript{56} A third study carried out in western Algeria, where there is a high rate of consanguineous marriages, failed to show an association of DR3 with diabetes, but there was an association with DR4 and DR3/DR4 alleles.\textsuperscript{57}

Several studies have been performed on the diabetic population of Tunisia. All studies showed a positive association with DR3 and DR4, and a strong association of the heterozygote genotype DR4-DQw8/DR3-DQw2 to type 1 diabetes.\textsuperscript{58-60} DR2 and DR5 were confirmed to play
a protective role in this population group. Similarly, Abid Kamoun et al have shown the DRB1*01501 DQB1*0602 and DRB1*11 DQB1*0301 haplotypes to be protective. The majority of studies that have focused on the HLA antigens (typed serologically) have been carried out in South Africa. In the first study, conducted in 1980, Briggs et al, found no increase in the frequency of B8 and B15, and no decrease in B7 in the 25 Xhosa type 1 diabetic patients. This is in contrast to what was observed in Caucasian type 1 diabetic patients. Hammond et al did find an increase in the frequency of B8 and B14 in 57 black South African diabetic patients. In 1983, Shires et al compared the frequency of HLA antigens in 72 Caucasian, and 53 black, type 1 diabetic patients. HLA A1 and B8 antigens were significantly increased, while A3 and B17 antigens were reduced in the Caucasian diabetic group. Only HLA B8 was increased in the black diabetic sample. Two studies were conducted by Omar et al, in which the HLA A, B and C antigen status were determined, in addition to DR typing, in black and Indian type 1 diabetic patients from South Africa. In the black patients, the frequency of DR4 was significantly higher compared to in the control subjects, and DR3/DR4 heterozygosity was associated with a greater relative risk for developing disease, compared to the presence of DR3 alone. Indian diabetic patients showed a significant increase in the frequency of B8, Aw24 and DR3 HLA antigens, compared to controls. A strong association was also observed with DR4 among patients of north Indian origin. A study conducted on black South African and coloured South African type 1 diabetic patients, showed a weak association with DRw9 in the black population, but failed to show any other associations commonly seen in black American type 1 diabetic patients. The coloured patients failed to show an association with B8 and DR3, but did have an increased frequency of DR4 and a decreased frequency of DR2, commonly seen in Caucasian populations.

The latest South African study reported in the literature was published in 2001. In this study, Zulu diabetics [typed by polymerase chain reaction (PCR) with sequence-specific primers] showed the presence of the common susceptibility antigens: DR3, DR4, DQ2 and DR9. These findings were similar to those reported from other studies. One study carried out in Nigeria did not show an association of type 1 diabetes with DR4. The reason for this may be that DR4 correlates with an early age of onset in Caucasian type 1 diabetic patients, and the Nigerian patients in this study had an age of onset > 20 years.

Although susceptibility to type 1 diabetes is strongly associated with certain HLA alleles, other genetic loci also play a role in the triggering and/or development of the disease. The IDDM2 locus accounts for about 10% of the susceptibility toward type 1 diabetes. This locus maps to a variable number of tandem repeats (VNTR), or minisatellites, upstream of the insulin gene. The short class I VNTRs (30-44 repeats) predominate (70%) in Caucasians. The remaining alleles tend to fall into the longer class III category. The intermediate lengths (class II) are rare. Class I VNTR alleles predispose to type 1 diabetes, whereas the class III alleles have a dominant protective effect. The presence of at least one class III allele is associated with a threefold reduction in the risk of developing type 1 diabetes.

Undlien et al studied 488 type 1 diabetics from three different ethnic groups, Tanzanian blacks, Norwegian Caucasians and Japanese Orientals, to determine whether there was an association between polymorphisms in the insulin gene and the occurrence of type 1 diabetes. The presence of insulin gene polymorphisms conferred susceptibility in the Caucasian patients, as well as the Tanzanians. However, this tendency was not statistically significant. No association was observed in the Japanese population group.

Findings of the majority of genetic studies conducted in Africa are in agreement with those from studies carried out in Europe and America, namely that DR3 and DR4 are more common in type 1 diabetic patients, and that the heterozygote haplotype, DR3/DR4, is strongly associated with type 1 diabetes. A number of studies also support the protective role of DR2 and DQ6. There are also some haplotypes that are unique to different regions in Africa. Larger studies are required among African populations to determine which haplotypes are suggestive of an increased risk of type 1 diabetes development in the different ethnic groups. Similarly, an insufficient number of studies have been carried out to determine whether or not there is an association between the different susceptibility genes and type 1 diabetes in Africa.

**Conclusion**

Little is known about the autoimmune role in the pathology of disease in African populations. One study has shown a lower prevalence of GAD autoantibodies in black South Africans, compared to data obtained from Caucasian type 1 diabetic patients. There is some evidence of ethnic differences in the autoimmune response. This needs to be further investigated, using the measurement of GAD, IA-2 and insulin autoantibodies. The latter two autoantibodies have never been investigated in the South African black population.

It should also be borne in mind that the prevalence of type 1 diabetes is thought to be lower in Africans than Europeans. Therefore, there may also be significant ethnic differences.
in both the aetiology and pathology of the disease.32 Further research into the aetiology and pathology of type 1 diabetes in Africa needs to be conducted, as the information will help to characterise diabetes in the different population groups. This will provide important information on the role of the immune system in the disease aetiology, particularly in black Africans, for whom there are currently little such data.

References

1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-1053.

2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2005;28(Suppl 1):S37-S42.

3. Flint A and Arslanian S. Treatment of type 2 diabetes in youth. Diabetes Care. 2011;34(Suppl 2):S177-S183.

4. Rosenbloom AL, Joe JR, Young RS, Winter WE. Emerging epidemic of type 2 diabetes in youth. Diabetes Care. 1999;22(2):345-354.

5. Eisenbarth GS. Type 1 diabetes mellitus. A chronic autoimmune disease. New Engl J Med. 1986;314(21):1360-1368.

6. Gorsuch AN, Spencer KM, Lister J, et al. Evidence for a long prediabetic period in type 1 (insulin-dependent) diabetes mellitus. Lancet. 1981;2(8260-61):1363-1366.

7. Elamin A, Omer MI, Hofvander Y, Tuvemo T. Prevalence of IDDM in Sudanese children in Khartoum, Sudan. Diabetes Care. 1989;12(6):430-432.

8. Rewers M, Laporte RE, King H, Tuomilehto J. Trends in the prevalence and incidence of diabetes: insulin-dependent diabetes mellitus in childhood. World Health Stat Q. 1998;41(3-4):179-189.

9. Diabetes Epidemiology Research International Group. Geographic patterns of childhood insulin-dependent diabetes mellitus. Diabetes. 1988;37(8):1113-1119.

10. Karvonen M, Vilk-Kajander M, Moltchanova E, et al. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetologia. 2000;43(10):1516-1526.

11. Bessonoud K, Boudraa G, Deschamps I, et al. Epidemiology of juvenile insulin–dependent diabetes in Algeria (Wilaya of Oran). Rev Epidemiol Sante Publique. 1990;38(2):91-99.

12. Alemu S, Dessie A, Seid E, et al. Insulin-requiring diabetes in rural Ethiopia: should we reopen the case for malnutrition-related diabetes? Diabetologia. 2009;52(9):1842-1845.

13. Patel N, Purohit M, Jadhav SK, et al. Prevalence of diabetes mellitus in rural Indian children. Indian J Pediatr. 2006;73(10):785-789.

14. Kadiki OA, Roaeid RB. Incidence of type 1 diabetes in Tanzania (1981-1985). Diabetes Res Clin Pract. 1988;9(3):219-224.

15. Panz VR, Kalk WJ, Zouvanis M, Joffe BI. Distribution of autoantibodies to glutamic acid decarboxylase across the spectrum of diabetes mellitus seen in South Africa. Diabetologia. 2002;45(6):783-791.

16. Christie MR, Vohra G, Champagne P, et al. Distinct antibody specificities to a 64–kD islet cell antigen in type 1 diabetes as revealed by tpsrin treatment. J Exp Med. 1990;172(3):789-794.

17. Palmer JP, Asplin CM, Clemons P, et al. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science. 1988;229(4950):1337-1339.

18. Mrena S, Savola K, Kulmala P, et al. Staging of preclinical type 1 diabetes in siblings of affected children. Childhood Diabetes Finland Study Group. Pediatrics. 1999;104(1 Pt 1):925-930.

19. Peters WH, Lester FT, Kohnert KD, Hildmann W. The frequency of islet cell surface antibodies in newly diagnosed diabetics from Ethiopia. Exp Clin Endocrinol. 1988;87(3):326-332.

20. Heleni F, Bard I, Chamnakh M, et al. Immunogenic heterogeneity in type 1 (insulin-dependent) diabetes among the Tunisian population, HLA-DR antigens and organ-specific autoantibodies (family study). J Autoimmun. 1991;3(3):553-561.

21. Fakhfakh R, Raddou S, Hadj Hamida YB, et al. Pancreatic autoantibodies in Tunisian children with newly diagnosed type 1 diabetes. Pathol Biol. 2008;56(3):130-132.

22. Elamin A, Omer MI, Tuvemo T. Islet-cell antibodies and endogenous insulin secretion in Sudanese diabetic children. Diabetes Res Clin Pract. 1992;16(2):91-96.

23. Elamin A, Omer MI, Tuvemo T. Islet-cell antibodies and endogenous insulin secretion in Sudanese diabetic children. Diabetes Res Clin Pract. 1994;1(1):188-192.

24. Oli JM, Bottazzo GF, Doniach D. Islet cell antibodies and diabetes in Nigerian. Trop Geogr Med. 1981;33(2):161-164.

25. McLarty DG, Ahadike I, Bottazzo GF, et al. Islet-cell antibodies are not specifically associated with insulin-dependent diabetes in Tanzanian Africans. Diabetes Res Clin Pract. 1990;3(3):219-224.

26. Elkind A, Khelfi N, Abd A, et al. Prevalence of anti-GAD autoantibodies in Tunisian children with type 1 diabetes. Tunis Med. 2002;80(5):281-285.

27. Libman IM, Pietropaolo M, Aslanian SA, et al. Evidence for heterogeneous pathogenesis of insulin-treated diabetes in black and white children. Diabet Care. 2003;26(10):2676-2682.

28. Ha wa MI, Picardi A, Costanzo F, et al. Frequency of diabetes and thyroid autoantibodies in patients with autoimmune endocrine disease from Cameroon. Clin Immunol. 2006;118(2-3):229-232.

29. Lutale JJK, Thordarson H, Holm PT, et al. Islet cell autoantibodies in African patients with type 1 and type 2 diabetes in Dar es Salaam Tanzania: a cross sectional study. J Autoimmun Dis. 2007;4:4.

30. Omar MA, Bottazzo GF, Aslam AC. Islet cell antibodies and other autoantibodies in South African blacks and Indians with insulin dependent diabetes mellitus (IDDM). Horm Metab Res. 1986;18(2):126-128.

31. Punz VR, Kalk WJ, Zouvanis M, Joffe BI. Distribution of autoantibodies to glutamic acid decarboxylase across the spectrum of diabetes mellitus seen in South Africa. Diabet Med. 2000;17(7):524-527.

32. Rheder P, Stolk RP, Grobble DE. Ethnic differences in C-peptide levels and anti-GAD antibodies in South African patients with diabetic ketoacidosis. QJM. 2001;94(1):39-43.

33. Pietropaolo M, Barinas-Mitchell E, et al. Evidence of islet cell autoimmunity in elderly patients with type 2 diabetes. Diabetes. 2000;49(1):32-38.

34. Tuomi T, Group LC, Zimmet PZ, et al. Antibodies to glutamic acid
Review Article: The epidemiology and pathogenesis of type 1 diabetes mellitus in Africa

decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes. 1993;42(2):359-362.

45. Groop LC, Bottazzo GF, Doniach D. Islet cell antibodies identify latent type 1 diabetes in patients aged 35-75 years at diagnosis. Diabetes. 1986;35(2):237-241.

46. Harris MI, Zimmet P. Classification of diabetes mellitus and other categories of glucose intolerance. In: Keen H, DeFronzo R, Alberti K and Zimmet P, editors. The international textbook of diabetes mellitus. London: Wiley; 1992; p. 3-18.

47. Otieno CF, Huho AN, Omonge EO, et al. Type 2 diabetes mellitus: clinical and aetiological types, therapy and quality of glycaemic control of ambulatory patients. East Afr Med J. 2008;85(1):24-29.

48. Patterson CG, Dahlquist GG, Gyürüs E, et al. EURODIAB Study Group. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet. 2009;373(9680):2027-2033.

49. Moltchanova EV, Schreier N, Lammi N, et al. Incidence of childhood type 1 diabetes mellitus in children worldwide. Diabet Med. 2009;26(7):673-678.

50. Dahlquist G, Gustavsson KH, Holmgren G, et al. The incidence of diabetes mellitus in Swedish children 0-14 years of age. A prospective study 1977-1980. Acta Paediatr Scand. 1982;71(1):7-14.

51. Ajuwon ZA, Olaleye OD, Omilabu SA, Baba SS. Complement fixing antibodies against selected viruses in diabetic patients and non-diabetic control subjects in Ibadan, Nigeria. Rev Roum Virol. 1992;43(1-2):3-5.

52. Pirie FJ, Famuyiwa OA, Owubo JA, et al. HLA-DQA1 and DQB1 study in Algerian type 1 diabetes families. Am J Hum Genet. 2001;69(4):820-830.

53. Cox NJ, Wapelhorst B, Morrison VA, et al. Seven regions of the genome show evidence of linkage to type 1 diabetes in a consensus analysis of 767 multiplex families. Am J Hum Genet. 2001;69(4):820-830.

54. Wolf E, Spencer KM, Cudworth AG. The genetic susceptibility to type 1 (insulin-dependent) diabetes: analysis of the HLA-DR association. Diabetologia. 1983;24(4):224-230.

55. Mercier P, Vallo JJ, Vailettes B, Vague P. HLA-A, B, DR antigens and insulin-dependent diabetes in Algerians. Tissue Antigens. 1985;26(1):20-24.

56. Beressi JP, Djoulah S, Khalil I, et al. HLA DQA1 and DQB1 study in Algerian type 1 diabetes families. Diabetologia. 1992;35(8):451-458.

57. Aribi M, Moulessehoul S, Benabadj B, Kendoucitani M. HLA DR phenotypic frequencies and genetic risk of Type 1 diabetes in west region of Algeria, Tlemcen. BMC Genet. 2004;5:24-30.

58. Ayed K, Bard R, Gorg Y, et al. HLA A, B, and DR antigens and complotype in Tunisian patients with diabetes mellitus. Dis Markers. 1989;7(1):43-47.

59. Jenhani F, Bardi R, Ayed K, et al. Extended HLA haplotypes in multiplex families with insulin dependent diabetes mellitus in Tunisian population: HLA serological typing and RFLP analysis. Dis Markers. 1990;8(8):327-331.

60. Abid Kamoun H, Hmida S, Kaabi H, et al. HLA polymorphism in type 1 diabetes Tunisians. Ann Genet. 2002;45(1):45-50.

61. Briggs BR, Jackson WP, Du Toit ED, Botha MC. The histocompatibility (HLA) antigen distribution in diabetes in southern African Blacks (Xhosa). Diabetes. 1980;29(1):68-71.

62. Hammond MG, Aslam AC, Omar MA. HLA and insulin-dependent diabetes in South African negroes. Diabetologia. 1980;19(2):101-102.

63. Shires R, Maier G, Lustig A, et al. HLA antigens in White and Black South African diabetics. S Afr Med J. 1983;64(28):1087-1089.

64. Omar MA, Hammond MG, Aslam AC. HLA-A, B, C and DR antigens in young South African blacks with Type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1984;26(1):20-23.

65. Omar MA, Hammond MG, Rajput MC, Aslam AC. HLA A, B, C and DR antigens in young South African Indians with insulin-dependent diabetes mellitus. S Afr Med J. 1984;66(20):765-767.

66. Oren A, Taljaard D, de Toit E, HLA-A, B, C and DR antigen associations in insulin dependent diabetes mellitus (IDDM) in South African Negros (black) and Cape coloured people. Tissue Antigens. 1985;26(5):332-339.

67. Pire FJ, Hammond MG, Motala AA, Omar MA. HLA class II antigens in South African Blacks with type I diabetes. Tissue Antigens. 2001;57(4):348-352.

68. Shires R, Maier G, Lustig A, et al. HLA-DQA1 and DQB1 study in black type I diabetics in Nigeria. Further support for models of inheritance. Diabetes. 1986;35(5):583-589.

69. Bennett ST, Luessen AM, Gough SC, et al. Susceptibility to human type 1 diabetes at IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite locus. Nat Genet. 1995;9(3):284-292.

70. Vafadis P, Ouniissi-Benkalha H, Palumbo M, et al. Class III alleles of the variable number of tandem repeat insulin polymorphism associated with silencing of thymic insulin predispose to type 1 diabetes. J Clin Endocrinol Metab. 2001;86(8):3705-3710.

71. Udendie DE, Hamaguchi K, Kimura A, et al. IDDM susceptibility associated with polymorphisms in the insulin gene region. A study of blacks, Caucasians and orientals. Diabetologia. 1994;37(8):745-749.

72. Karvonen M, Vii-Kajander M, Moltchanova E, et al. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care. 2000;23(10):1516-1526.